SecBot SecBot
SECBOTREPLAY Home › Report › CPRX

CPRX · Catalyst Pharmaceuticals filed additional definitive proxy soliciting…

CATALYST PHARMACEUTICALS, INC. · DEFA14A filed May 12, 2026 at 09:05 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed May 12, 2026 at 09:05 ET

Catalyst Pharmaceuticals filed additional definitive proxy soliciting materials (DEFA14A) containing an employee update email from the CEO regarding the pending acquisition by Angelini Pharma. The email confirms Q1 2026 revenues of $149.4 million (28.2% YoY growth) and reiterates the expected closing in Q3 2026. This is a routine communication to employees and does not contain new material information for shareholders beyond what was previously disclosed.

  • Filing is a DEFA14A containing an employee email from Catalyst CEO regarding the Angelini Pharma acquisition.
  • Q1 2026 revenues were $149.4 million, representing 28.2% year-over-year growth, including $135.6 million from FIRDAPSE and AGAMREE.
  • Transaction expected to close in Q3 2026; integration planning underway.
  • Catalyst will enter a quiet period, continuing quarterly earnings reports but suspending investor calls and conferences.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access